Consulting on reproductive toxicology for contraceptive development
Official title: TOXICOLOGY CONSULTING FOR REPRODUCTIVE SCIENCE and Contraception Research
Funded at Leading Edge Pharmtox, LLC · NIH-11180591 · Data updated 2026-11-12
This study is all about helping create safer and more effective birth control options for everyone by looking closely at how these methods affect reproductive health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leading Edge Pharmtox, LLC NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | August 25, 2024 |
| Project end | August 24, 2025 |
| Funding year | 2024 |
| Award (this year) | $20,000 |
| NIH project number | 75N94024P00543-0-0-1 |
| Project ID | NIH-11180591 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals seeking new contraceptive methods or those interested in the safety and efficacy of existing options.
✕Less likely to help
Patients who are not interested in contraceptive methods or those who have already found suitable contraceptive options may not benefit from this research.
What this research studies
This research focuses on providing expert consulting services in reproductive toxicology to support the development of new contraceptives for both men and women. The project involves rigorous design and execution of studies related to reproductive pharmacology and toxicology. By leveraging specialized knowledge, the research aims to enhance the safety and efficacy of contraceptive methods. Patients may benefit from improved contraceptive options that are developed based on thorough toxicological assessments.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective contraceptive options for patients.
How similar studies have gone: Previous research in reproductive toxicology has shown promise in improving contraceptive safety and efficacy, indicating that this approach is grounded in established scientific principles.
Where this research is happening
-
Leading Edge Pharmtox, LLC
Durham, United States Active
Researchers
- Principal investigator: Kelce, William — Leading Edge Pharmtox, LLC
- Study coordinator: Kelce, William
Related research
Other NIH-funded projects on the same topics.
-
Mobile health support to boost PrEP and contraception use among young women in Zambia
A mobile health program helps female university students in Zambia learn about and access HIV prevention and contraception.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Long‑lasting antibody vaginal ring for non‑hormonal birth control
Testing a vaginal ring that slowly releases an antibody to trap sperm and prevent pregnancy for people seeking non‑hormonal contraception.
-
A woman-controlled, nonhormonal on-demand contraceptive device
This project is creating a woman-controlled vaginal device that releases a fabric-like polymer which thickens on contact with semen to help prevent pregnancy.
-
Vaginal ring releasing non-hormonal antibody contraception for month-long use
A monthly vaginal ring delivers a non-hormonal antibody-based contraceptive, offering a convenient, user-controlled option for women who want to avoid daily dosing or invasive procedures.
-
On-demand non-hormonal vaginal contraception with a fast-dissolving antibody tablet
A new on-demand vaginal tablet dissolves quickly to release a monoclonal antibody for non-hormonal contraception.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.